EWTX Insider Trading (Edgewise Therapeutics)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $10,250,000.00
Insider Selling (Last 12 Months): $0.00
Edgewise Therapeutics Insider Trading History Chart
Edgewise Therapeutics Share Price & Price History
$26.05
As of 06/22/2021 01:13 PM ET
Revealed: A Real Solution for Depression?
From Investing Trends | Ad
Depression is the leading cause of disability worldwide. For nearly 100 million people… there's no known solution. That's right. Nearly one-third of the world's 322 million people suffering from depression have no existing treatment. But that's all about to change.
Here's how you could capitalize off this
Edgewise Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/30/2021 | James E Flynn | Major Shareholder | Buy | 625,000 | $16.00 | $10,000,000.00 | 4,962,207 |  |
| 3/30/2021 | Jonathan D Root | Director | Buy | 15,625 | $16.00 | $250,000.00 | 15,625 | |
SEC Filings (Institutional Ownership Changes) for Edgewise Therapeutics (NASDAQ:EWTX)
91.84% of Edgewise Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
Edgewise Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/21/2021 | Citadel Advisors LLC | 2,382,148 | $77.42M | 0.0% | N/A | 4.836% |  |
| 5/19/2021 | Logos Global Management LP | 1,056,812 | $34.35M | 3.4% | N/A | 2.146% | |
| 5/19/2021 | Octagon Capital Advisors LP | 125,000 | $4.06M | 1.5% | N/A | 0.254% | |
| 5/19/2021 | Squarepoint Ops LLC | 20,185 | $0.66M | 0.0% | N/A | 0.041% | |
| 5/18/2021 | Baker BROS. Advisors LP | 500,000 | $16.25M | 0.1% | N/A | 1.015% | |
| 5/18/2021 | Millennium Management LLC | 60,077 | $1.95M | 0.0% | N/A | 0.122% | |
| 5/18/2021 | RA Capital Management L.P. | 2,613,623 | $84.94M | 1.3% | N/A | 5.306% | |
| 5/18/2021 | Orbimed Advisors LLC | 13,944,680 | $453.20M | 4.2% | N/A | 29.316% | |
| 5/18/2021 | Cormorant Asset Management LP | 2,340,914 | $74.31M | 1.7% | N/A | 4.921% | |
| 5/18/2021 | Citadel Advisors LLC | 2,382,148 | $77.42M | 0.0% | N/A | 5.008% | |
| 5/17/2021 | Viking Global Investors LP | 3,352,249 | $108.95M | 0.3% | N/A | 7.047% | |
| 5/17/2021 | Deerfield Management Company L.P. Series C | 3,933,137 | $127.83M | 2.7% | N/A | 8.269% | |
| 5/17/2021 | Woodline Partners LP | 357,429 | $11.62M | 0.3% | N/A | 0.751% | |
| 5/17/2021 | EcoR1 Capital LLC | 1,224,175 | $39.79M | 1.8% | N/A | 2.574% | |
| 5/17/2021 | Caas Capital Management LP | 30,000 | $0.98M | 0.0% | N/A | 0.063% | |
| 5/17/2021 | Janus Henderson Group PLC | 2,140,908 | $65.15M | 0.0% | N/A | 4.501% | |
| 5/17/2021 | Sphera Funds Management LTD. | 100,000 | $3.25M | 0.2% | N/A | 0.210% | |
| 5/17/2021 | Novo Holdings A S | 5,587,207 | $181.58M | 7.5% | N/A | 11.746% | |
| 5/17/2021 | Goldman Sachs Group Inc. | 65,263 | $2.12M | 0.0% | N/A | 0.137% | |
| 5/14/2021 | Credit Suisse AG | 84,052 | $2.73M | 0.0% | N/A | 0.177% | |
| 5/13/2021 | Federated Hermes Inc. | 616,724 | $20.04M | 0.0% | N/A | 1.297% | |
| 5/12/2021 | New Leaf Venture Partners L.L.C. | 1,553,661 | $50.49M | 11.9% | N/A | 3.266% | |
| 5/11/2021 | Landscape Capital Management L.L.C. | 8,923 | $0.29M | 0.0% | N/A | 0.019% | |
Data available starting January 2016
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Read More on Edgewise Therapeutics
Today's Range
Now: $26.05
52 Week Range
Now: $26.05
Volume
664 shs
Average Volume
189,901 shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Edgewise Therapeutics?
Edgewise Therapeutics' top insider investors include:
- James E Flynn (Major Shareholder)
- Jonathan D Root (Director)
Who are the major institutional investors of Edgewise Therapeutics?
Edgewise Therapeutics' top institutional investors include:
- Orbimed Advisors LLC — 29.32%
- Novo Holdings A S — 11.75%
- Deerfield Management Company L.P. Series C — 8.27%
- Viking Global Investors LP — 7.05%
- RA Capital Management L.P. — 5.31%
- Citadel Advisors LLC — 5.01%
Which institutional investors are buying Edgewise Therapeutics stock?
In the previous quarter, EWTX stock was bought by institutional investors including:
- Orbimed Advisors LLC
- Novo Holdings A S
- Deerfield Management Company L.P. Series C
- Viking Global Investors LP
- RA Capital Management L.P.
- Citadel Advisors LLC
- Citadel Advisors LLC
- Cormorant Asset Management LP
Within the last year, these company insiders have bought Edgewise Therapeutics stock:
- James E Flynn (Major Shareholder)
- Jonathan D Root (Director)
